1naresh
Array
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
1nareshArray
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
Table 1: Clinical data of 10 patients with VAFAs
Patient No. Age (yr) Sex Ruptured Treatment Follow-Up Case 1 46 Male No 3 EP 8 mo, cured Case 2 53 Male No 2 EP 12 mo, thrombosis formation Case 3 39 Female Yes 2 EP+coils Withdraw Case 4 37 Male Yes 2 EP+coils 6 mo, cured Case 5 51 Male No 2 EP+coils 7 mo, thrombosis formation Case 6 59 Male No 3 EP 13 mo, cured Case 7 49 Female Yes 2 EP+coils 12 mo, cured Case 8 46 Male Yes 3 EP+coils 12 mo, cured Case 9 60 Male No 2 EP 6 mo, stable Case10 46 Male No 2 EP 12 mo, thrombosis formation
Note:—EP indicates Enterprise self-expanding stent.